Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31194365 | 0.86 | BRD4 (0.42) | BRD4APPPIK3C3ALOX5APFEN1 | |
| SCHEMBL31078377 | 0.81 | HSD17B10 (0.45) | BRD4APPPIK3C3KCNH2METAP2 | |
| SCHEMBL26823824 | 0.80 | BRD4 (0.39) | BRD4APPPIK3C3ALOX5APFEN1 | |
| SCHEMBL586478 | 0.75 | BRD4 (0.51) | BRD4APPPIK3C3SYKMMP12 | |
| SCHEMBL21100918 | 0.74 | SCN10A (0.39) | SCN10AKCNH2PDE10ASYKMETAP2 | |
| SCHEMBL15829280 | 0.74 | SCN10A (0.43) | SCN10AKCNH2PDE10AMETAP2 | |
| SCHEMBL19682171 | 0.74 | BRD4 (0.41) | BRD4APPPIK3C3ALOX5APFEN1 | |
| SCHEMBL15058223 | 0.72 | AHR (0.47) | BRD4APPPIK3C3 | |
| SCHEMBL761114 | 0.72 | PRKCI (0.53) | BRD4SCN10AKCNH2METAP2MMP12 | |
| SCHEMBL17449428 | 0.72 | DYRK1A (0.53) | SCN10AKCNH2PDE10ASYKMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | Eil Therapeutics, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD (CN) | 2023-04-27 | — | — | US | disclosed |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-8802688-B2 | Substituted acetyl-coa carboxylase inhibitors | PFIZER INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8580828-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. | 2013-05-02 | — | — | US | disclosed |
| US-20120270893-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8268871-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC | 2012-05-03 | — | — | US | disclosed |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-7795282-B2 | Mitotic kinesin inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2010-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109656-A1 | MITOTIC KINESIN INHIBITORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | BRD4 811/4885APP 3451/4885PIK3C3 1345/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | BRD4 1582/4885APP 3418/4885PIK3C3 199/4885 |
| US-11834450-B2 | Compounds having ((3-nitrophenyl)sulfonyl)acetamide as BCL-2 inhibitors | BCL2, BCL2A1, BCL2L1 | BRD4 281/4885APP 560/4885PIK3C3 1624/4885 |
| US-11814379-B2 | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | ERBB2, EGFR, ERBB3 | BRD4 234/4885APP 1511/4885PIK3C3 1128/4885 |
| US-11384066-B1 | Heterocyclic compounds useful as aurora a selective inhibitors | AURKA, AURKC, AURKB | BRD4 681/4885APP 4142/4885PIK3C3 985/4885 |
| US-20230064360-A1 | HETEROCYCLES AND USES THEREOF | KRAS, HRAS, TP53 | BRD4 147/4885APP 3789/4885PIK3C3 631/4885 |
| US-20120142671-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | BRD4 458/4885APP 2761/4885PIK3C3 160/4885 |
| US-20230026271-A1 | Piperazine Compounds for Inhibiting CPS1 | CPS1, CPSF1, CPSF7 | BRD4 397/4885APP 4664/4885PIK3C3 4258/4885 |
| US-20120108619-A1 | N1/N2-LACTAM ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, COASY | BRD4 1413/4885APP 864/4885PIK3C3 4367/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | BRD4 3175/4885APP 3064/4885PIK3C3 980/4885 |
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | BRD4 3179/4885APP 789/4885PIK3C3 3866/4885 |
| US-20230128198-A1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS AURORA A SELECTIVE INHIBITORS | AURKA, AURKC, AURKB | BRD4 619/4885APP 4281/4885PIK3C3 1214/4885 |
| US-20140018399-A1 | MITOTIC KINESIN INHIBTORS AND METHODS OF USE THEREOF | KIF5B, KIF2C, KIFC1 | BRD4 1108/4885APP 3395/4885PIK3C3 1396/4885 |
| US-20100331283-A1 | Mitotic kinesin inhibitors and methods of use thereof | KIF5B, KIF2C, KIFC1 | BRD4 811/4885APP 3451/4885PIK3C3 1345/4885 |
| US-20120270893-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | BRD4 766/4885APP 2062/4885PIK3C3 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.